This guide is written for pharmaceutical companies, contract manufacturers, startups, overseas businesses, and importers planning human-medicine operations in the UK. Getting licensing right matters because it underpins patient safety, product quality, traceability, and legal compliance from day one.
Terms like MIA, MIA(IMP), MS, GMP, and MHRA get thrown around constantly, but they're often misunderstood in practice. This guide breaks down licence types, eligibility, documentation, the application and inspection process, ongoing obligations, common mistakes, and situations where a different authorisation is actually what you need.
Key Takeaways
- Distinguish an MIA from marketing authorisation, WDA(H), veterinary, and controlled-drug licences.
- MHRA assesses premises, personnel, PQS, GMP controls, and imports as one package.
- Base the application on live systems, not plans you still intend to build.
- Verify fees, forms, and timelines against current MHRA sources before you file.
- Treat approval as the start of ongoing GMP, reporting, variation, and inspection duties.
What Is a UK Drug Manufacturing Licence and Why Is It Required?
The Manufacturer's/Importer's Authorisation (MIA) is the core licence covering manufacturing, assembly, and specified importation of human medicinal products at MHRA-approved sites. It's issued under regulation 17 of the Human Medicines Regulations 2012, which names manufacture, assembly, defined imports, and possession for those purposes as the licensable activities.
Three related categories exist, and they're not interchangeable:
| Licence | Covers | Legal basis |
|---|---|---|
| MIA | Manufacture/assembly of licensed medicines, specified imports, batch certification | HMR 2012, regulation 17 |
| MIA(IMP) | Manufacture, assembly, or import of investigational medicinal products | Clinical Trials Regulations 2004, Part 6 |
| MS | Manufacture/assembly of unlicensed "specials" for individual patient needs | HMR 2012 special-needs provisions |
These categories can shift as regulations evolve, so confirm the current legal scope with the MHRA or official guidance before relying on it.
How an MIA Differs From Other Permissions
An MIA is frequently confused with other authorisations:
- Marketing authorisation concerns permission to place a specific medicine on the market, not permission to make it.
- WDA(H) covers wholesale distribution of human medicines, a distinct activity from manufacturing or importing.
- Veterinary medicines, controlled drugs, active substances, and clinical-trial activities may need additional or separate permissions entirely.
The licence exists to make sure medicines are consistently manufactured, protected from contamination and mix-ups, properly documented, and traceable through the supply chain. This consistency is why a tablet from one batch performs identically to the next.
Who Actually Needs One
Businesses that typically need an MIA, MIA(IMP), or MS include:
- Manufacturers and contract manufacturing organisations (CMOs)
- Repackagers or assemblers (over-labelling counts as licensable assembly)
- Importers bringing products in from outside recognised arrangements
- Businesses performing operations on behalf of another marketing authorisation holder
The practical test is activity-based, not aspirational. Answer these questions honestly before assuming you need (or don't need) a licence:
- What does the business physically do, and which products does it handle?
- Where does each activity happen?
- Does it import, manufacture, assemble, test, release, or store product?
UK Drug Manufacturing Licence Requirements
MHRA assesses your complete operating model, not just your company registration or a product list on paper. That means personnel, premises, documentation, and manufacturing controls all have to hold together as one coherent system.
Qualified Person and Key Personnel Requirements
You'll need appropriately qualified personnel with defined authority, responsibilities, availability, and clear reporting lines. For most MIA holders, this includes a Qualified Person (QP) responsible for batch certification or release.
Schedule 7 of the HMR sets out the usual QP route: a relevant qualifying university course of at least four years plus two years of specified practical experience, though alternatives exist for longer courses with shorter experience.
These aren't universal eligibility rules. Verify current qualification requirements for your specific product and activity, since MS licences use a different model built around a trained, QC-approved releasing officer rather than a QP.
Build in:
- Training records and demonstrable competence
- Up-to-date job descriptions with clear delegation
- Coverage arrangements for absence (QP cover is a classic inspection gap)
Premises, Facilities, and Equipment
For every proposed site, MHRA expects a clear description of layout, material and personnel flows, controlled areas, storage arrangements, and segregation between material or product statuses.
You'll need to demonstrate your premises and equipment genuinely suit the products and processes involved, covering:
- Cleaning and maintenance schedules
- Calibration records
- Environmental monitoring
- Contamination-control measures
Sterile, biological, temperature-sensitive, or hazardous products carry additional expectations around containment and environmental control. Don't treat these as an afterthought; they're often where inspections stall.
Pharmaceutical Quality System and GMP Documentation
Your quality system needs to cover:
- Quality manual and SOPs
- Deviation and CAPA processes
- Change control and document control
- Complaints handling and recall procedures
- Supplier qualification and self-inspection
Procedures must match what actually happens on the floor. Validation evidence, batch documentation, testing arrangements, and data-integrity controls all need to back up what your SOPs claim.
Manufacturing, Testing, Validation, and Outsourcing
Define every manufacturing and testing step clearly. Back each step with:
- Technical agreements and specifications
- Process and cleaning validation
- Computerised systems controls
Where contract manufacturers, laboratories, or storage providers are involved, MHRA expects risk-based oversight and written agreements that spell out exactly who's responsible for what.
Pre-application readiness checklist:
- Corporate details and legal entity confirmation
- Site Master File information
- Personnel qualification and training records
- Premises plans and equipment qualification records
- Quality system documentation
- Product and process descriptions
- Import arrangements (if applicable)
- Evidence the system is operational, not theoretical
How to Apply for a UK Drug Manufacturing Licence
Step 1: Confirm the Correct Authorisation and Scope
Map every proposed activity against current MHRA and Human Medicines Regulations requirements, covering manufacturing, assembly, importing, testing, batch certification, investigational products, specials, and any controlled-drug activity. Define the legal entity, named sites, dosage forms, product categories, operations, and markets the application will cover.
Step 2: Establish an Inspection-Ready Operation
Appoint required personnel, implement your Pharmaceutical Quality System, qualify suppliers and contractors, complete relevant validation, and make sure premises and equipment match what you're submitting.
An aspirational application (one describing what you plan to have in place) creates delays. If inspectors find procedures, staff knowledge, records, or facilities that don't match the submission, you're starting over.
Step 3: Compile and Submit the Application
MHRA publishes separate new-application forms for manufacturer/importer (MIA), investigational products, and specials. Applications and supporting documents go to MHRA's process licensing team by email, and MHRA invoices the new-application fee separately. Identify the current form and submission route using live official sources, since forms get updated.
Present your licence scope precisely. Vague descriptions of manufacturing or importing activities invite questions and slow everything down.
Step 4: Prepare for MHRA Review and Inspection
Inspectors assess premises, equipment, personnel, documentation, production controls, quality-control systems, supplier oversight, data integrity, and your ability to manage deviations, complaints, recalls, and changes.
Observations get answered through documented root-cause analysis, with:
- Named owners for each corrective action
- Realistic deadlines
- Objective evidence that the action was actually completed
Step 5: Receive the Authorisation and Verify Its Scope
Once granted, review the licence for the named legal entity, approved premises, permitted activities, product categories, and any conditions attached. You cannot begin activities outside this approved scope without first obtaining the appropriate variation, notification, or additional permission.
On current costs: MHRA's published fee schedule lists a standard manufacturer application fee of £4,209, with GMP inspection charged separately at £5,251 per day (not a flat one-off total). A standard variation runs £688, an administrative variation £345, and there's an annual periodic fee of £561. These figures change, so confirm against the live schedule before budgeting.
MHRA guidance indicates a new application should take around 90 working days, with variations typically taking 30 working days, or 90 if inspection is required. These are indicative targets, not guarantees: inspection findings and deficiency responses can extend them considerably.
Ongoing Compliance, Scope and Licence Maintenance
An MIA isn't a one-time registration. It's an ongoing regulatory relationship with continuing GMP compliance and recurring inspection exposure, assessed on a risk basis, including short-notice and triggered visits.
Recurring obligations include:
- Batch and manufacturing records, retained per current retention rules
- Quality-control testing and equipment calibration
- Training updates and competence reviews
- Deviation, CAPA, and change control management
- Complaints and recall handling
- Supplier qualification and data integrity checks
- Regular self-inspection
When a Variation Is Required
Changes in any of these areas can trigger a variation, notification, or fresh regulatory assessment:
- Premises, equipment, products, or processes
- Legal ownership or key personnel
- Manufacturing activities or outsourced providers
Don't assume a change is minor just because it feels administrative internally. MHRA's variation categories distinguish standard changes (like a new named person or site address) from purely administrative ones (like a contact detail update).
How It Interacts With Other Permissions
An MIA doesn't automatically cover marketing authorisation obligations, WDA(H) requirements for separate wholesale activity, controlled-drug licensing, or veterinary and investigational product permissions. Each operates on its own legal basis and needs separate assessment if your operations expand into that territory.
Maintaining current records isn't optional busywork. It's what lets you demonstrate continuous compliance the moment an inspector walks in, scheduled or not.
Related group support: If your UK manufacturing plans sit alongside Indian group operations, VJM Global can help with India entity formation, accounting, and tax compliance. That work is separate from MHRA licensing and is not a substitute for specialist UK regulatory advice.
Common Issues and When an MIA May Not Be Appropriate
A few misconceptions come up repeatedly. None of these automatically grant manufacturing permission:
- Company incorporation
- Holding a marketing authorisation
- GMP certification from elsewhere
- A WDA(H)
- Using a third-party manufacturer
Why Applications Stall
Common reasons MHRA delays or challenges an application:
- Premises don't match the submission: missing segregation, environmental controls, security, or equipment qualification evidence.
- Generic SOPs: copied from templates, with incomplete validation or weak data-integrity controls.
- Unclear accountability: insufficiently trained personnel or fuzzy reporting lines.
- Blurred activity boundaries: the application fails to distinguish manufacturing, importing, testing, release, wholesale, brokering, and storage as separate activities.
When You Might Need a Different Permission
An MIA alone won't cover everything. You may need a separate or additional authorisation for:
- Veterinary manufacturing
- Controlled drugs
- Active-substance activities
- Wholesale distribution or brokering
- Clinical-trial manufacturing
- Direct-to-patient supply arrangements
Conversely, an MIA may not be necessary at all. That includes businesses that only provide administrative services, act purely as a broker, or contract with an already-authorised manufacturer without performing any licensable activity themselves.
Where that boundary is unclear, get case-specific regulatory advice rather than guessing.
Regulatory disclaimer: Licence categories, fees, forms, and processing expectations change. Confirm current requirements directly with MHRA and seek professional advice for complex products, import routes, or multi-site operations before committing resources.
Conclusion
A UK drug manufacturing licence succeeds when the legal entity, manufacturing or importing activities, premises, personnel, quality system, documentation, and inspection evidence all line up consistently. There's no shortcut around that alignment.
The correct licence category depends entirely on what your business actually does, where it operates, which products it handles, and whether additional permissions apply on top.
Treat approval as the start of continuing GMP compliance, not the finish line. Before you commit:
- Verify current MHRA guidance before you submit
- Resolve any classification or scope uncertainty first
- Hold off on premises, personnel, or commercial contracts until scope is clear
Frequently Asked Questions
What is an MIA licence in the UK?
An MIA (Manufacturer's/Importer's Authorisation) permits specified manufacturing, assembly, and/or import activities for medicinal products at MHRA-approved sites, subject to ongoing GMP requirements.
Who needs a UK drug manufacturing licence?
Manufacturers, assemblers, eligible importers, and contract manufacturing operations typically need one. The exact answer depends on your products, activities, sites, and import route.
How do I apply for an MIA licence in the UK?
Classify your activities correctly, appoint required personnel, prepare premises and your Pharmaceutical Quality System, then submit through MHRA's current route. Inspection and deficiency correction follow before approval.
What documents are required for a UK drug manufacturing licence?
You'll need corporate and site details, personnel qualifications, manufacturing and quality procedures, validation evidence, product and process information, outsourcing agreements, and the current MHRA application forms.
How long does the MHRA approval process take?
Timing depends on application completeness, licence type, inspection scheduling, and how quickly you close deficiencies. Check current MHRA guidance for the latest processing expectations.
What is the difference between an MIA and a WDA(H)?
An MIA covers specified manufacturing or importing activities, while a WDA(H) covers wholesale distribution of human medicines. One authorisation doesn't automatically cover the other's activities.
